Use the Back button in your browser to see the other results of your search or to select another record.
| Effect of automated oxygen titration during walking on dyspnea and endurance in chronic hypoxemic patients with COPD: a randomized crossover trial |
| Kofod LM, Westerdahl E, Kristensen MT, Brocki BC, Ringbaek T, Hansen EF |
| Journal of Clinical Medicine 2021 Nov;10(21):4820 |
| clinical trial |
| 5/10 [Eligibility criteria: Yes; Random allocation: Yes; Concealed allocation: No; Baseline comparability: No; Blind subjects: No; Blind therapists: No; Blind assessors: Yes; Adequate follow-up: Yes; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed* |
|
The need for oxygen increases with activity in patients with COPD and on long-term oxygen treatment (LTOT), leading to periods of hypoxemia, which may influence the patient's performance. This study aimed to evaluate the effect of automated oxygen titration compared to usual fixed-dose oxygen treatment during walking on dyspnea and endurance in patients with COPD and on LTOT. In a double-blinded randomised crossover trial, 33 patients were assigned to use either automated oxygen titration or the usual fixed-dose in a random order in two walking tests. A closed-loop device, O2matic delivered a variable oxygen dose set with a target saturation of 90 to 94%. The patients had a home oxygen flow of (mean +/- SD) 1.6 +/- 0.9 L/min. At the last corresponding isotime in the endurance shuttle walk test, the patients reported dyspnea equal to median (IQR) 4 (3 to 6) when using automated oxygen titration and 8 (5 to 9) when using fixed doses, p < 0.001. The patients walked 10.9 (6.5 to 14.9) min with automated oxygen compared to 5.5 (3.3 to 7.9) min with fixed-dose, p < 0.001. Walking with automated oxygen titration had a statistically significant and clinically important effect on dyspnea. Furthermore, the patients walked for a 98% longer time when hypoxemia was reduced with a more well-matched, personalised oxygen treatment.
|